{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:58:29Z","timestamp":1761562709932,"version":"3.40.5"},"reference-count":24,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>Pembrolizumab is an immune checkpoint inhibitor designed to block the interaction between programmed cell death\u20101 and programmed cell death\u2010ligands 1 and 2. It shows efficacy in the treatment of patients with advanced nonsmall\u2010cell lung cancer, among others. Side effects may involve immune\u2010related adverse events, including vitiligo.<\/jats:p><jats:p>We hereby present a 63\u2010year\u2010old Caucasian female with metastatic nonsmall\u2010cell lung cancer. Immunohistochemical analysis showed programmed death\u2010ligand 1 expression on 100% of tumour cells. The patient was eligible for immunotherapy and received pembrolizumab every 3\u00a0weeks as the first\u2010line treatment. Three months after initiation of immunotherapy with pembrolizumab, depigmentation appeared on her upper right thoracic area of the skin overlying the affected lung lobe. Immunotherapy was generally well tolerated. Excellent response in our subject with complete remission during 16\u00a0months of follow\u2010up potentially indicates that cutaneous immune\u2010related adverse events, such as vitiligo, might be associated with increased efficacy of pembrolizumab in metastatic lung adenocarcinoma.<\/jats:p>","DOI":"10.1111\/bcp.14663","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T04:06:12Z","timestamp":1605931572000},"page":"2614-2618","source":"Crossref","is-referenced-by-count":11,"title":["Pembrolizumab\u2010induced vitiligo in a patient with lung adenocarcinoma: A case report"],"prefix":"10.1111","volume":"87","author":[{"given":"Vedrana","family":"Bulat","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology University Hospital Centre Sestre Milosrdnice  Vinogradska cesta Zagreb 29 Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1413-4862","authenticated-orcid":false,"given":"Robert","family":"Likic","sequence":"additional","affiliation":[{"name":"University of Zagreb School of Medicine  Zagreb Croatia"},{"name":"Associate Professor, Division for Clinical Pharmacology and Therapeutics Department of Internal Medicine University Hospital Centre Zagreb  Kispaticeva 12 Zagreb Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lada","family":"Bradic","sequence":"additional","affiliation":[{"name":"Department of Cardiology University Hospital Centre Zagreb  Kispaticeva 12 Zagreb Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhart","family":"Speeckaert","sequence":"additional","affiliation":[{"name":"Department of Dermatology Ghent University Hospital; De Pintelaan 185  Ghent Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija Delas","family":"Azdajic","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology University Hospital Centre Sestre Milosrdnice  Vinogradska cesta Zagreb 29 Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-014-1457-7"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0121"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2707"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00195"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0298-5"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.11.011"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2019.60.552"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2274"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.3579"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4756"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13867"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2011.00945.x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-427013"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2010.00703.x"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.044"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0923-1811(94)90057-4"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250291"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5715.148"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1975.tb03148.x"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15091847"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14663","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14663","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T16:37:24Z","timestamp":1693413444000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,10]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/bcp.14663"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14663","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2020,12,10]]}}}